Board of Directors
Shlomo Ben-Haim, MD, D.Sc – Co-Founder
Dr. Ben-Haim is the co-founder of a number of successful medical and biomedical companies in the fields of congestive heart failure, obesity, diabetes, esthetics and cosmetics, anti-viral medications, deep vein thrombosis prevention, therapy for limb ischemia and post-stroke and sports-injury rehabilitation. His formal education is in the fields of nuclear physics, mathematics, biomedical engineering, philosophy and medicine. He has held faculty appointments as a Professor of Medicine, Physiology and Biophysics, at Harvard University and the Technion – Israel Institute of Technology. Dr. Ben-Haim has published over 100 scientific papers in peer-reviewed journals and holds over 180 patents and patent applications.
Fred Hrkac –Executive Chairman
Fred Hrkac is a 22 year veteran in the medical device industry, having worked 15 years with Johnson & Johnson in the start-up of the Central Eastern Europe operations, and as Vice President International for the Biosense Webster division. Most recently he was President of Boston Scientific, Europe, Middle East and Africa running a $2 billion P&L. Fred has spent 11 years in Electrophysiology/CRM working in Boston Scientific, Sorin CRM and Biosense Webster.
Dan S. Suesskind- Director
Dan has been with Teva since 1976. He has been Chief Financial Officer from 1978 to 2008 and a member of the board from 1981-2001. From 1970 until 1976 he was a Consultant and Securities Analyst with International Consultants Ltd. He received his B.A. in Economics and Political Science from the Hebrew University in 1965 and an M.B.A. from the University of Massachusetts in 1969.
Dr. Simos Kedikoglou, MD, CFA, MBA – Director
Dr. Simos Kedikoglou is the President of the MedInvest group. He was previously a Corporate Vice President of Business Development for Boston Scientific with responsibility for acquisitions, licensing and distribution deals in the US, Europe and Asia. Prior to Boston Scientific, Simos was an Associate Partner with McKinsey & Company in the US, focusing on M&A and has advised clients in completed healthcare deals with a combined value of $45 billion. Simos holds a Medical Degree from the University of Athens, Greece, an MBA with distinction and a Master’s in Public Health from Harvard University, and he is a CFA Charterholder.
Antony Owers, FCA – Director
Mr. Owers joined Impulse Dynamics N.V. in 2001 and is responsible for all aspects of the Curaçao-based Company. He was with the accounting firm KPMG from 1969-98 in London, São Paulo, Brazil and Curaçao, the latter as a Senior Partner for many years. He has been a Fellow of the Institute of Chartered Accountants in England and Wales since 1980, and has been British consul to the Dutch Caribbean islands since 1997. He is also treasurer of many charitable foundations in the Netherlands Antilles including the Red Cross, International School, National Trust, Consular Corps, Rotary and Uniting for Children.
Guillaume (Guy) H.J. Suverkropp, MD. , FACC., FCCP., HRS Reg.,Cardiologist– Director
A cardiologist by profession, Dr. Suverkropp has been educated and trained in the Netherlands. He began his career as a Cardiologist in 1983, specializing in Electrophysiology and Pacemaker devices, and serving as Chief consultant of the Catharina Ziekenhuis in Eindhoven, the Netherlands. In 1993 he established a D.C. Cardiology Practice with a complete non-invasive cardiac laboratory in Curacao, where he currently serves as Managing Director. The practice serves the 3 local hospitals, but also patients from around the island province. Dr. Suverkropp has published several scientific publications in Cardiology, and has previously held faculty appointments as Assistent Professor of Cardiology at St.Martinus University and International Medical University of Saba.
Search the Site
From our blog
- July 2012 Meet us at the European Society of Cardiology Annual Congress, Munich, August 2012
- May 2012 Cardiostim 2012 June 13-16, 2012
- April 2012 German Society of Cardiology (DGK) Congress, Mannheim
- April 2012 Not All Heart Failure Patients Benefit from CRT
- April 2012 New article published in the Int. J. of Cardiology compares LV reverse remodeling induced by CCM and CRT